BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 25190611)

  • 1. Re: Cesare Cozzarini, Claudio Fiorino, Chiara Deantoni, et al. Higher-than-expected severe (grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Eur urol 2014;66:1024-30.
    De Bari B; Alongi F; Arcangeli S
    Eur Urol; 2014 Dec; 66(6):e111-2. PubMed ID: 25190611
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Berardino De Bari, Filippo Alongi, Stefano Arcangeli's letter to the editor re: Cesare Cozzarini, Claudio Fiorino, Chiara Deantoni, et al. Higher-than-expected severe (grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Eur urol 2014;66:1024-30.
    Cozzarini C; Fiorino C; Briganti A; Montorsi F; Di Muzio N
    Eur Urol; 2014 Dec; 66(6):e113-4. PubMed ID: 25199719
    [No Abstract]   [Full Text] [Related]  

  • 3. Re:Mark K. Buyyounouski. Radiobiological modeling and the study of hypofractionated radiotherapy for prostate cancer. Eur Urol 2014;66:1031-2.
    Fiorino C; Briganti A; Cozzarini C
    Eur Urol; 2015 Mar; 67(3):e56-7. PubMed ID: 25466947
    [No Abstract]   [Full Text] [Related]  

  • 4. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients.
    Cozzarini C; Fiorino C; Deantoni C; Briganti A; Fodor A; La Macchia M; Noris Chiorda B; Rancoita PM; Suardi N; Zerbetto F; Calandrino R; Montorsi F; Di Muzio N
    Eur Urol; 2014 Dec; 66(6):1024-30. PubMed ID: 24985964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiobiological modeling and the study of hypofractionated radiotherapy for prostate cancer.
    Buyyounouski MK
    Eur Urol; 2014 Dec; 66(6):1031-2. PubMed ID: 25130566
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01.
    Mak RH; Hunt D; Efstathiou JA; Heney NM; Jones CU; Lukka HR; Bahary JP; Patel M; Balogh A; Nabid A; Leibenhaut MH; Hamstra DA; Roof KS; Jeffrey Lee R; Gore EM; Sandler HM; Shipley WU
    Urol Oncol; 2016 Oct; 34(10):430.e1-7. PubMed ID: 27381895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints.
    Peters M; van der Voort van Zyp J; Hoekstra C; Westendorp H; van de Pol S; Moerland M; Maenhout M; Kattevilder R; van Vulpen M
    Radiother Oncol; 2015 Nov; 117(2):262-9. PubMed ID: 26349590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical factors predicting late severe urinary toxicity after postoperative radiotherapy for prostate carcinoma: a single-institute analysis of 742 patients.
    Cozzarini C; Fiorino C; Da Pozzo LF; Alongi F; Berardi G; Bolognesi A; Briganti A; Broggi S; Deli A; Guazzoni G; Perna L; Pasetti M; Salvadori G; Montorsi F; Rigatti P; Di Muzio N
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):191-9. PubMed ID: 21109361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
    Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
    Eur Urol; 2011 Dec; 60(6):1142-8. PubMed ID: 21855208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of changing rectal dose volume parameters over time on late rectal and urinary toxicity after high-dose intensity-modulated radiotherapy for prostate cancer: A 10-years single centre experience.
    Fonteyne V; Sadeghi S; Ost P; Vanpachtenbeke F; Vuye P; Lumen N; De Meerleer G
    Acta Oncol; 2015 Jun; 54(6):854-61. PubMed ID: 25387271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships between bladder dose-volume/surface histograms and acute urinary toxicity after radiotherapy for prostate cancer.
    Carillo V; Cozzarini C; Rancati T; Avuzzi B; Botti A; Borca VC; Cattari G; Civardi F; Esposti CD; Franco P; Girelli G; Maggio A; Muraglia A; Palombarini M; Pierelli A; Pignoli E; Vavassori V; Zeverino M; Valdagni R; Fiorino C
    Radiother Oncol; 2014 Apr; 111(1):100-5. PubMed ID: 24631144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer.
    Lock M; Best L; Wong E; Bauman G; D'Souza D; Venkatesan V; Sexton T; Ahmad B; Izawa J; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1306-15. PubMed ID: 20708855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
    Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urologic Complications Following Pelvic Radiotherapy.
    Lobo N; Kulkarni M; Hughes S; Nair R; Khan MS; Thurairaja R
    Urology; 2018 Dec; 122():1-9. PubMed ID: 30036617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy.
    Marks LB; Carroll PR; Dugan TC; Anscher MS
    Int J Radiat Oncol Biol Phys; 1995 Mar; 31(5):1257-80. PubMed ID: 7713787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy.
    Wong GW; Palazzi-Churas KL; Jarrard DF; Paolone DR; Graf AK; Hedican SP; Wegenke JD; Ritter MA
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):449-55. PubMed ID: 17869014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting toxicity in radiotherapy for prostate cancer.
    Landoni V; Fiorino C; Cozzarini C; Sanguineti G; Valdagni R; Rancati T
    Phys Med; 2016 Mar; 32(3):521-32. PubMed ID: 27068274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.
    Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.